Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
Summary
We are grateful for the support of our new investor syndicate, a group that shares our commitment to save sight and improve eye care with potentially transformative therapies. Additionally, we look forward to sharing the topline results from our OCS-02 Phase 2b RELIEF trial later this quarter.In connection with the Financing, Oculis accepted Subscription Offers from a syndicate of new Icelandic institutional and existing investors. Oculis intends to use the net proceeds from the Financing to advance and accelerate its clinical development pipeline, as well as for working capital and general corporate purposes. There will be no public offering of Shares in the United States.Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.For more information, please visit: www.oculis.comThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the commencement of trading of Oculiss ordinary shares on the Main Market and the use of proceeds, timing and closing of the Financing, and the potential of Oculis to deliver anticipated clinical readouts, including the expected OCS-02 RELIEF Phase 2b topline data readout.